Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atea Pharmaceuticals Inc | AVIR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.00 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.765 - 5.19 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 4.00 | USD |
Atea Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
336.66M | 84.16M | - | 0 | -116.59M | -1.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atea Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVIR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.05 | 4.06 | 3.805 | 3.98 | 271,635 | -0.05 | -1.23% |
1 Month | 4.12 | 4.60 | 3.805 | 4.18 | 358,210 | -0.12 | -2.91% |
3 Months | 3.11 | 4.60 | 3.01 | 3.88 | 461,405 | 0.89 | 28.62% |
6 Months | 3.17 | 4.60 | 2.765 | 3.45 | 431,011 | 0.83 | 26.18% |
1 Year | 3.77 | 5.19 | 2.765 | 3.66 | 502,280 | 0.23 | 6.10% |
3 Years | 75.27 | 79.57 | 2.765 | 14.31 | 1,068,703 | -71.27 | -94.69% |
5 Years | 29.94 | 94.1737 | 2.765 | 15.68 | 990,012 | -25.94 | -86.64% |
Atea Pharmaceuticals Description
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. |